Bachem : FY 2023 Presentation

Date	|	March 7, 2024
Location	|	Zurich / Zoom Call
Name	|	Thomas Meier, Alain Schaffter

At the end of the presentation there will be time for questions.

Write to us in the Q&A SECTION anytime.

This call will be recorded and playback will be posted on bachem.com.

2 Bachem FY Results 2023

3 Bachem FY Results 2023

01

02

Full Year Results 2023 - Thomas Meier

Financial Review 2023 - Alain Schaffter

03 Outlook 2024 - Thomas Meier

04 Q & A - all

4 Bachem FY Results 2023

Thomas Meier

5 Bachem FY Results 2023

Sales

• Sales of CHF 577.3m (+8.6%).
• Local currency increase +12.8%.
• Strong H2/23 with CHF 337.5m (+13.7% against H2/22).
• Key drivers CMC development (petides & oligonucleotides) and commercial peptides.

Capacity

• Building K commissioning and start up in H2/24.
• Additional equipment building G to support key accounts during 2024.
• Sisslerfeld: site development plan handed in
• 2 006 full-time equivalent employees (+230).

Profitability

• EBITDA CHF 166.7m / margin 28.9% (29.1% adjusted).
• Local currencies EBITDA margin 30.5%.
• Proposal to increase dividend to CHF 0.80 per share (increase of CHF 0.05).

Portfolio

• CMC pipeline with 162 NCEs.
• Includes several new NCEs despite biotech funding environment.

6 Bachem FY Results 2023

in CHF million	2023	Change in CHF	Change in	Sales share
local currency
Research & Specialties	40.8	- 13.5%	- 10.4%	7.1%
CMC Development	227.5	+ 22.4%	+ 27.7%	39.4%
	309.0
Commercial API	+ 3.4%	+ 7.1%	53.5%
Total sales	577.3	+ 8.6%	+ 12.8%	100.0%

7 Bachem FY Results 2023

Commercial API:

• Originator peptides, including first sales from strategic long-term customers.
• Generic peptides.

CMC development:

• Strong peptide project landscape.
• Strong oligonucleotide development growth.

Commercial API:

• Lower commercial oligonucleotide sales.
• Reduced demand for small molecule generics.

Research & Specialties

• Tight capacity for small-scalenon-medical projects due to high API demand.

8 Bachem FY Results 2023

Tailwinds

+8.6%

HEADWINDS

+13.7%

338

		297
	264
239	235	240
225

179177

135

2019

2020

2021

2022

2023

H1 sales H2 sales

9 Bachem FY Results 2023

Sales distribution by customer tiers in % of sales

100.0%

90.0%

80.0%

70.0%

60.0%

50.0%

40.0%

30.0%

20.0%

10.0%

0.0%

2019

2020

2021

2022

2023

Top 5 Top 6-10 Top 11-15 Other

10 Bachem FY Results 2023

Top 10 customers c. 63% of sales